Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421 | 1.00 | CYP2C19 (0.42) | CYP2C19FFAR3SMN1; SMN2ALDH1A1USP2 | |
| Hydrochloric Acid SCHEMBL11825341 | 0.97 | CYP2C19 (0.41) | CYP2C19FFAR3SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL6913628 | 0.97 | CYP2C19 (0.41) | CYP2C19FFAR3SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL6914795 | 0.97 | CYP2C19 (0.41) | CYP2C19FFAR3SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL6917016 | 0.97 | CYP2C19 (0.41) | CYP2C19FFAR3SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL6909889 | 0.97 | CYP2C19 (0.41) | CYP2C19FFAR3SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL6917012 | 0.97 | CYP2C19 (0.41) | CYP2C19FFAR3SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL6914957 | 0.97 | CYP2C19 (0.41) | CYP2C19FFAR3SMN1; SMN2ALDH1A1USP2 | |
| Hydrochloric Acid SCHEMBL11815475 | 0.97 | CYP2C19 (0.41) | CYP2C19FFAR3SMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL6915754 | 0.97 | CYP2C19 (0.41) | CYP2C19FFAR3SMN1; SMN2ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861031-A | Ester compound, preparation method and application thereof, and lubricating oil composition | 中国石油化工股份有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-113862058-B | Lubricating oil composition and preparation method thereof | 中国石油化工股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-113861032-A | Ester compound, preparation method and application thereof, and lubricating oil composition | 中国石油化工股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113862058-A | Lubricating oil composition and preparation method thereof | 中国石油化工股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113861031-A | Ester compound, preparation method and application thereof, and lubricating oil composition | 中国石油化工股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| WO-2020162471-A1 | PYRIDONE DERIVATIVE | マルホ株式会社 | 2020-08-13 | — | — | WO | disclosed |
| CN-110198937-A | N- (5- morpholino thiazol-2-yl) Carbox amide and its preparation method and application | 华东理工大学 | 2019-09-03 | — | — | CN | disclosed |
| US-7915266-B2 | Promoting microtube polymerization; drug resistant cancer; 5-Azepan-1-yl-7-chloro-6-(2,4,6-trifluorophenyl)imidazo[1,2-a]pyrimidine | WYETH HOLDINGS CORPORATION (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1663241-B1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7524849-B2 | Antitumor agents to treat multiple drug resistant tumors; promoters of microtubule polymerization; etherification | WYETH HOLDINGS CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| WO-2005030775-A1 | 6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | WYETH (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2005030216-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050065167-A1 | 6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents | WYETH HOLDINGS CORPORATION (US) | 2005-03-24 | — | — | US | disclosed |
| US-4402981-A | ANTIULCER AGENT | KALI-CHEMIE PHARMA, GMBH (DE) | 1983-09-06 | — | — | US | disclosed |
| US-4365032-A | ANTIOXIDANTS FOR POLYMERS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1982-12-21 | — | — | US | disclosed |
| US-4191770-A | ANTIULCER AGENTS, ANTISECRETORY AGENTS | KALI-CHEMIE PHARMA GMBH (DE) | 1980-03-04 | — | — | US | disclosed |
| US-4001218-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
| US-3982011-A | ANTIBIOTICS, ANIMAL GROWTH PROMOTERS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-21 | — | — | US | disclosed |
| US-3931153-A | BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065167-A1 | 6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents | ABCC1, TUBB3, ABCB1 | CYP2C19 4288/4885FFAR3 4088/4885SMN1; SMN2 1719/4885 |
| US-20050075357-A1 | 5-arylpyrimidines as anticancer agents | DPYD, ABCC1, ARF5 | CYP2C19 3473/4885FFAR3 4116/4885SMN1; SMN2 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.